The Conversation (0)
BioLineRx (TLV:BLRX) said this week that it has filed the necessary regulatory submissions with Finnish health authorities to start a Phase 1/2 trial for BL-7010, a treatment for celiac disease.
BioLineRx (TLV:BLRX) said this week that it has filed the necessary regulatory submissions with Finnish health authorities to start a Phase 1/2 trial for BL-7010, a treatment for celiac disease.
As quoted in the market news:
The Phase 1/2 study is a two-part (single and repeated), double-blind, placebo-controlled, dose escalation study of BL-7010 in 32 patients at a world-leading site for celiac disease research in Finland. The primary objective of the study is to assess the safety of single and repeated ascending doses of BL-7010 in well-controlled celiac patients.
Click here for the full press release by BioLineRx (TLV:BLRX)